Form 4: Verastem CEO Dan Paterson Granted 213,785 RSUs

Verastem, Inc. CEO and Director Dan Paterson received a grant of 213,785 restricted stock units, vesting over three years.

Summary

• Dan Paterson, President and CEO, and a Director of Verastem, Inc. (VSTM), was granted 213,785 Restricted Stock Units (RSUs).
• The RSUs were granted on January 21, 2026, under the company's Amended and Restated 2021 Equity Incentive Plan.
• Each RSU represents the contingent right to receive one share of Verastem Common Stock.
• The RSUs will vest in three equal annual installments of 33.3% on the first three anniversaries of January 21, 2026, with full vesting by January 21, 2029.
• Vesting is contingent upon Mr. Paterson's continued service as an employee or service provider to Verastem.
• Following this transaction, Mr. Paterson beneficially owns 613,889 shares of Common Stock directly.

Sentiment

Score: 7

Explanation: The grant of RSUs to the CEO is a positive signal for management retention and alignment with shareholder interests, indicating continued commitment. It's a standard compensation practice, not directly indicative of immediate operational performance, hence a moderately positive score.

Positives

• The grant of 213,785 Restricted Stock Units (RSUs) to President and CEO Dan Paterson aligns his long-term interests with those of shareholders.
• The three-year vesting schedule incentivizes Mr. Paterson's continued leadership and commitment to the company's performance.
• The equity grant is a standard component of executive compensation, aimed at retaining key talent.

Negatives

• The issuance of new equity through RSU vesting could lead to a degree of share dilution for existing shareholders over time.

Future Outlook

NA

Industry Context

Executive equity grants, such as Restricted Stock Units (RSUs), are a common compensation practice in the biotechnology and pharmaceutical industries. They are used to attract, retain, and incentivize key leadership by aligning their financial interests with the long-term performance of the company, which is particularly crucial in industries with long development cycles and high R&D costs like biotech.

Related Party Transactions

• The grant of 213,785 Restricted Stock Units to Dan Paterson, the President and CEO, constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through aligned management incentives; potential for minor dilution upon vesting of RSUs.
• Employees: May set a precedent for executive compensation structures and incentives within the company.
• Management: Provides significant long-term equity compensation tied to continued service.

Next Steps

• Continued service of Dan Paterson to ensure vesting of RSUs.
• Future vesting events on the anniversaries of January 21, 2026, until January 21, 2029.

Key Dates

Keywords

Verastem, VSTM, Form 4, Restricted Stock Units, RSU, Equity Grant, Insider Transaction, Executive Compensation, Dan Paterson, Biotechnology